Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Review on Nanostructured Lipid Carriers as Promising Drug Delivery Vehicle to Target Various Cancers via Oral Route: A Step towards “Chemotherapy at Home”

Author(s): Sheikh Shahnawaz Quadir, Garima Joshi*, Vinod Saharan, Harish Mangesh, Deepak Choudhary, Khushwant Yadav, Chandra Prakash Jain and Lalit Singh Chauhan

Volume 14, Issue 2, 2024

Published on: 16 November, 2023

Page: [127 - 142] Pages: 16

DOI: 10.2174/0124681873272867231113192452

Price: $65

Abstract

Oral drug administration is largely preferred owing to enhanced patient compliance, convenience of self-intake of dose, non-invasiveness, and low manufacturing cost. Cancer is a condition that starts with aberrant cell division at an uncontrolled rate. The clinical effectiveness of many anticancer drugs is limited by their physicochemical characteristics and physiological circumstances in the GI tract. Nanostructured lipid carriers have the potential to enhance the bioavailability of anticancer drugs by entrapping them. The NLCs, by virtue of their nanosize and their biocompatibility, can bypass the first-pass metabolism and be taken up by M cells of Peyer’s patches to deliver the drug to the deeper tumours. The proposed review highlights the potential of NLCs in oral drug delivery for the management of various cancers. It discusses various strategies, method of preparation, mechanism of uptake, and their applications in the treatment of cancer via oral delivery. Further, it explains the recent advances and future perspectives.

Keywords: Oral drug delivery, GALT, NDDS, lipids, NLCs, cancer, nanocarriers, nanotechnology.

« Previous Next »
Graphical Abstract

[1]
Soni NK, Sonali LJ, Singh A, Mangla B, Neupane YR, Kohli K. Nanostructured lipid carrier potentiated oral delivery of raloxifene for breast cancer treatment. Nanotechnology 2020; 31(47): 475101.
[http://dx.doi.org/10.1088/1361-6528/abaf81] [PMID: 32886644]
[2]
Harshita , Barkat MA, Rizwanullah M, et al. Harshita, Barkat MA, Rizwanullah M, Beg S, Pottoo FH, Siddiqui S, Ahmad FJ. Paclitaxel-loaded nanolipidic carriers with improved oral bioavailability and anticancer activity against human liver carcinoma. AAPS PharmSciTech 2019; 20(2): 87.
[http://dx.doi.org/10.1208/s12249-019-1304-4]
[3]
Chivere VT, Kondiah PPD, Choonara YE, Pillay V. Nanotechnology-based biopolymeric oral delivery platforms for advanced cancer treatment. Cancers (Basel) 2020; 12(2): 522.
[http://dx.doi.org/10.3390/cancers12020522] [PMID: 32102429]
[4]
Gilani SJ, Bin-Jumah M, Rizwanullah M, et al. Chitosan coated luteolin nanostructured lipid carriers: optimization, in vitro-ex vivo assessments and cytotoxicity study in breast cancer cells. Coatings 2021; 11(2): 158.
[http://dx.doi.org/10.3390/coatings11020158]
[5]
Khatun Z, Nurunnabi M, Reeck GR, Cho KJ, Lee Y. Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy. J Control Release 2013; 170(1): 74-82.
[http://dx.doi.org/10.1016/j.jconrel.2013.04.024] [PMID: 23665255]
[6]
Bhardwaj V, Ankola DD, Gupta SC, Schneider M, Lehr CM, Kumar MNVR. PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res 2009; 26(11): 2495-503.
[http://dx.doi.org/10.1007/s11095-009-9965-4] [PMID: 19756974]
[7]
Sorasitthiyanukarn FN, Muangnoi C, Ratnatilaka Na Bhuket P, Rojsitthisak P, Rojsitthisak P. Chitosan/alginate nanoparticles as a promising approach for oral delivery of curcumin diglutaric acid for cancer treatment. Mater Sci Eng C 2018; 93: 178-90.
[http://dx.doi.org/10.1016/j.msec.2018.07.069] [PMID: 30274050]
[8]
Singh A, Neupane YR, Panda BP, Kohli K. Lipid Based nanoformulation of lycopene improves oral delivery: formulation optimization, ex vivo assessment and its efficacy against breast cancer. J Microencapsul 2017; 34(4): 416-29.
[http://dx.doi.org/10.1080/02652048.2017.1340355 ] [PMID: 28595495]
[9]
Verma P, Meher JG, Asthana S, Pawar VK, Chaurasia M, Chourasia MK. Perspectives of nanoemulsion assisted oral delivery of docetaxel for improved chemotherapy of cancer. Drug Deliv 2016; 23(2): 479-88.
[http://dx.doi.org/10.3109/10717544.2014.920430] [PMID: 24901205]
[10]
Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004; 113(1-3): 151-70.
[http://dx.doi.org/10.1016/j.jbiotec.2004.06.007] [PMID: 15380654]
[11]
Pouton CW. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 2006; 29(3-4): 278-87.
[http://dx.doi.org/10.1016/j.ejps.2006.04.016] [PMID: 16815001]
[12]
Chen CC, Tsai TH, Huang ZR, Fang JY. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: Physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 2010; 74(3): 474-82.
[http://dx.doi.org/10.1016/j.ejpb.2009.12.008] [PMID: 20060469]
[13]
Chime SA, Attama AA, Builders PF, Onunkwo GC. Sustained-release diclofenac potassium-loaded solid lipid microparticle based on solidified reverse micellar solution: in vitro and in vivo evaluation. J Microencapsul 2013; 30(4): 335-45.
[http://dx.doi.org/10.3109/02652048.2012.726284] [PMID: 23057661]
[14]
Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Deliv Rev 2008; 60(6): 734-46.
[http://dx.doi.org/10.1016/j.addr.2007.09.006] [PMID: 18045728]
[15]
Nasirizadeh S, Malaekeh-Nikouei B. Solid lipid nanoparticles and nanostructured lipid carriers in oral cancer drug delivery. J Drug Deliv Sci Technol 2020; 55: 101458.
[http://dx.doi.org/10.1016/j.jddst.2019.101458]
[16]
Shidhaye S, Vaidya R, Sutar S, Patwardhan A, Kadam V. Solid lipid nanoparticles and nanostructured lipid carriers--innovative generations of solid lipid carriers. Curr Drug Deliv 2008; 5(4): 324-31.
[http://dx.doi.org/10.2174/156720108785915087] [PMID: 18855604]
[17]
Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution. United States Patent US 5,250,236, 1993.
[18]
Lucks S, Müller R. Arzneistoffträger aus festen lipidteilchen (feste lipidnanosphären (sln)). EP Patent 0605497B2, 1993.
[19]
Das S, Ng WK, Tan RBH. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci 2012; 47(1): 139-51.
[http://dx.doi.org/10.1016/j.ejps.2012.05.010] [PMID: 22664358]
[20]
Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009; 366(1-2): 170-84.
[http://dx.doi.org/10.1016/j.ijpharm.2008.10.003] [PMID: 18992314]
[21]
Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011; 12(1): 62-76.
[http://dx.doi.org/10.1208/s12249-010-9563-0] [PMID: 21174180]
[22]
Lim W, Rajinikanth PS, Mallikarjun C, Kang YB. Formulation and delivery of itraconazole to the brain using a nanolipid carrier system. Int J Nanomedicine 2014; 9: 2117-26.
[http://dx.doi.org/10.2147/IJN.S57565] [PMID: 24833900]
[23]
El-Helw AR, Fahmy U. Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers. Int J Nanomedicine 2015; 10: 5797-804.
[http://dx.doi.org/10.2147/IJN.S91556] [PMID: 26396513]
[24]
Wu M, Fan Y, Lv S, Xiao B, Ye M, Zhu X. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Drug Deliv 2016; 23(8): 2720-5.
[http://dx.doi.org/10.3109/10717544.2015.1058434] [PMID: 26203691]
[25]
Shah NV, Seth AK, Balaraman R, Aundhia CJ, Maheshwari RA, Parmar GR. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: Design and in vivo study. J Adv Res 2016; 7(3): 423-34.
[http://dx.doi.org/10.1016/j.jare.2016.03.002] [PMID: 27222747]
[26]
Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Saudi Pharm J 2021; 29(9): 999-1012.
[http://dx.doi.org/10.1016/j.jsps.2021.07.015] [PMID: 34588846]
[27]
Nordin N, Yeap SK, Zamberi NR, et al. Characterization and toxicity of citral incorporated with nanostructured lipid carrier. PeerJ 2018; 6: e3916.
[http://dx.doi.org/10.7717/peerj.3916] [PMID: 29312812]
[28]
Nordin N, Yeap SK, Rahman HS, et al. Antitumor and anti-metastatic effects of citral-loaded nanostructured lipid carrier in 4T1-induced breast cancer mouse model. Molecules 2020; 25(11): 2670.
[http://dx.doi.org/10.3390/molecules25112670] [PMID: 32526880]
[29]
Quadir SS, Saharan V, Choudhary D, Harish , Jain CP, Joshi G. Nano-strategies as Oral Drug Delivery Platforms for Treatment of Cancer: Challenges and Future Perspectives. AAPS PharmSciTech 2022; 23(5): 152.
[http://dx.doi.org/10.1208/s12249-022-02301-0] [PMID: 35606661]
[30]
Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: Recent advances in drug delivery. J Drug Target 2012; 20(10): 813-30.
[http://dx.doi.org/10.3109/1061186X.2012.716845 ] [PMID: 22931500]
[31]
Shukla T, Upmanyu N, Pandey SP, Gosh D. Lipid nanocarriers. In: Lipid Nanocarriers for Drug Targeting. William Andrew Publishing 2018; pp. 1-47.
[http://dx.doi.org/10.1016/B978-0-12-813687-4.00001-3]
[32]
Joshi G, Kumar A, Sawant K. Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery. Eur J Pharm Sci 2014; 60: 80-9.
[http://dx.doi.org/10.1016/j.ejps.2014.04.014] [PMID: 24810394]
[33]
Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: A novel drug targeting carrier. J Drug Deliv Sci Technol 2019; 51: 255-67.
[http://dx.doi.org/10.1016/j.jddst.2019.02.017]
[34]
Aghazadeh T, Bakhtiari N, Rad IA, Ramezani F. Formulation of kaempferol in nanostructured lipid carriers (NLCs): a delivery platform to sensitization of MDA-MB468 breast cancer cells to paclitaxel. Biointerface Res Appl Chem 2021; 11(6): 14591-601.
[http://dx.doi.org/10.33263/BRIAC116.1459114601]
[35]
Kanwar R, Uppal S, Mehta SK. Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs): Fabrication and functionalization for impending therapeutic applications. In: Functionalized Nanomaterials II. CRC Press 2021; pp. 57-70.
[36]
Vinchhi P, Patel JK, Patel MM. High-pressure homogenization techniques for nanoparticles. In: InEmerging Technologies for Nanoparticle Manufacturing. Cham: Springer International Publishing 2021; pp. 263-85.
[http://dx.doi.org/10.1007/978-3-030-50703-9_11]
[37]
Gomaa E, Fathi HA, Eissa NG, Elsabahy M. Methods for preparation of nanostructured lipid carriers. Methods 2022; 199: 3-8.
[http://dx.doi.org/10.1016/j.ymeth.2021.05.003] [PMID: 33992771]
[38]
Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol 2013; 7(1): 41-55.
[http://dx.doi.org/10.2174/187221013804484827] [PMID: 22946628]
[39]
Beloqui A, del Pozo-Rodríguez A, Isla A, Rodríguez-Gascón A, Solinís MÁ. Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs. J Drug Deliv Sci Technol 2017; 42: 144-54.
[http://dx.doi.org/10.1016/j.jddst.2017.06.013]
[40]
Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: A review. Pharmaceutics 2020; 12(3): 288.
[http://dx.doi.org/10.3390/pharmaceutics12030288 ] [PMID: 32210127]
[41]
Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother 2018; 103: 598-613.
[http://dx.doi.org/10.1016/j.biopha.2018.04.055] [PMID: 29677547]
[42]
Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol 2016; 44(1): 27-40.
[http://dx.doi.org/10.3109/21691401.2014.909822] [PMID: 24813223]
[43]
Gao S, McClements DJ. Formation and stability of solid lipid nanoparticles fabricated using phase inversion temperature method. Colloids Surf A Physicochem Eng Asp 2016; 499: 79-87.
[http://dx.doi.org/10.1016/j.colsurfa.2016.03.065]
[44]
Vanderhoff JW, El-Aasser MS, Ugelstad J. Polymer emulsification process. United States Patent US 4,177,177, 1979.
[45]
Bhagurkar AM, Repka MA, Murthy SN. A novel approach for the development of a nanostructured lipid carrier formulation by hot-melt extrusion technology. J Pharm Sci 2017; 106(4): 1085-91.
[http://dx.doi.org/10.1016/j.xphs.2016.12.015] [PMID: 28040458]
[46]
Carbone C, Cupri S, Leonardi A, Puglisi G, Pignatello R. Lipid-based nanocarriers for drug delivery and targeting: a patent survey of methods of production and characterization. Pharm Pat Anal 2013; 2(5): 665-77.
[http://dx.doi.org/10.4155/ppa.13.43] [PMID: 24237173]
[47]
Abedi Gaballu F, Abbaspour-Ravasjani S, Mansoori B, et al. Comparative of in-vitro evaluation between erlotinib loaded nanostructured lipid carriers and liposomes against A549 lung cancer cell line. Iran J Pharm Res 2019; 18(3): 1168-79.
[http://dx.doi.org/10.22037/ijpr.2019.1100775] [PMID: 32641930]
[48]
Zhu Y, Liang X, Lu C, et al. Nanostructured lipid carriers as oral delivery systems for improving oral bioavailability of nintedanib by promoting intestinal absorption. Int J Pharm 2020; 586: 119569.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119569] [PMID: 32592899]
[49]
Zhang T, Chen J, Zhang Y, Shen Q, Pan W. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 2011; 43(3): 174-9.
[http://dx.doi.org/10.1016/j.ejps.2011.04.005] [PMID: 21530654]
[50]
Gambhire VM, Salunkhe SM, Gambhire MS. Atorvastatin-loaded lipid nanoparticles: antitumor activity studies on MCF-7 breast cancer cells. Drug Dev Ind Pharm 2018; 44(10): 1685-92.
[http://dx.doi.org/10.1080/03639045.2018.1492605 ] [PMID: 29936872]
[51]
Sun B, Luo C, Li L, et al. Core-matched encapsulation of an oleate prodrug into nanostructured lipid carriers with high drug loading capability to facilitate the oral delivery of docetaxel. Colloids Surf B Biointerfaces 2016; 143: 47-55.
[http://dx.doi.org/10.1016/j.colsurfb.2016.02.065] [PMID: 27011346]
[52]
Ong YS, Saiful Yazan L, Ng WK, et al. Thymoquinone loaded in nanostructured lipid carrier showed enhanced anticancer activity in 4T1 tumor-bearing mice. Nanomedicine (Lond) 2018; 13(13): 1567-82.
[http://dx.doi.org/10.2217/nnm-2017-0322] [PMID: 30028248]
[53]
Sartaj A, Annu , Alam M, et al. Combinatorial delivery of Ribociclib and green tea extract mediated nanostructured lipid carrier for oral delivery for the treatment of breast cancer synchronising in silico, in vitro, and in vivo studies. J Drug Target 2022; 30(10): 1-22.
[http://dx.doi.org/10.1080/1061186X.2022.2104292 ] [PMID: 35856926]
[54]
Godugu C, Doddapaneni R, Safe SH, Singh M. Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer. Eur J Pharm Biopharm 2016; 108: 168-79.
[http://dx.doi.org/10.1016/j.ejpb.2016.08.006] [PMID: 27586082]
[55]
Moraes S, Marinho A, Lima S, et al. Targeted nanostructured lipid carriers for doxorubicin oral delivery. Int J Pharm 2021; 592: 120029.
[http://dx.doi.org/10.1016/j.ijpharm.2020.120029] [PMID: 33130218]
[56]
Fernandes RS, Silva JO, Seabra HA, et al. α- Tocopherol succinate loaded nano-structed lipid carriers improves antitumor activity of doxorubicin in breast cancer models In vivo. Biomed Pharmacother 2018; 103: 1348-54.
[http://dx.doi.org/10.1016/j.biopha.2018.04.139] [PMID: 29864917]
[57]
Wang L, Luo Q, Lin T, et al. PEGylated nanostructured lipid carriers (PEG-NLC) as a novel drug delivery system for biochanin A. Drug Dev Ind Pharm 2015; 41(7): 1204-12.
[http://dx.doi.org/10.3109/03639045.2014.938082] [PMID: 25010850]
[58]
Sabzichi M, Mohammadian J, Mohammadi M, et al. Vitamin D-loaded nanostructured lipid carrier (NLC): A new strategy for enhancing efficacy of doxorubicin in breast cancer treatment. Nutr Cancer 2017; 69(6): 840-8.
[http://dx.doi.org/10.1080/01635581.2017.1339820 ] [PMID: 28742387]
[59]
Jiang H, Pei L, Liu N, Li J, Li Z, Zhang S. Etoposide-loaded nanostructured lipid carriers for gastric cancer therapy. Drug Deliv 2016; 23(4): 1379-82.
[http://dx.doi.org/10.3109/10717544.2015.1048491 ] [PMID: 26162024]
[60]
Zhou X, Zhang X, Ye Y, et al. Nanostructured lipid carriers used for oral delivery of oridonin: An effect of ligand modification on absorption. Int J Pharm 2015; 479(2): 391-8.
[http://dx.doi.org/10.1016/j.ijpharm.2014.12.068] [PMID: 25556104]
[61]
Weingart SN, Brown E, Bach PB, et al. NCCN task force report: oral chemotherapy. J Natl Compr Canc Netw 2008; 6(S3) (Suppl. 3): S-1-S-14.
[http://dx.doi.org/10.6004/jnccn.2008.2003] [PMID: 18377852]
[62]
Jiang H, Geng D, Liu H, Li Z, Cao J. Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors. Drug Deliv 2016; 23(9): 3665-73.
[http://dx.doi.org/10.1080/10717544.2016.1217954 ] [PMID: 27749102]
[63]
Dong X, Wang W, Qu H, Han D, Zheng J, Sun G. Targeted delivery of doxorubicin and vincristine to lymph cancer: evaluation of novel nanostructured lipid carriers in vitro and in vivo. Drug Deliv 2016; 23(4): 1374-8.
[http://dx.doi.org/10.3109/10717544.2015.1041580 ] [PMID: 26208133]
[64]
Al Gailani M, Liu M, Wen J. Ligands for oral delivery of peptides across the blood-brain-barrier. Acta Materia Medica 2022; 1(1): 106-23.
[http://dx.doi.org/10.15212/AMM-2021-0007]
[65]
Miao YB, Chen KH, Chen CT, et al. A Noninvasive Gut-to-Brain Oral Drug Delivery System for Treating Brain Tumors. Adv Mater 2021; 33(34): 2100701.
[http://dx.doi.org/10.1002/adma.202100701] [PMID: 34270814]
[66]
Chen Y, Pan L, Jiang M, Li D, Jin L. Nanostructured lipid carriers enhance the bioavailability and brain cancer inhibitory efficacy of curcumin both in vitro and in vivo. Drug Deliv 2016; 23(4): 1383-92.
[http://dx.doi.org/10.3109/10717544.2015.1049719 ] [PMID: 26066035]
[67]
Emami J, Rezazadeh M, Sadeghi H, Khadivar K. Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box-Behnken design. Pharm Dev Technol 2017; 22(3): 370-82.
[http://dx.doi.org/10.1080/10837450.2016.1189933 ] [PMID: 27689412]
[68]
Borderwala K, Rathod S, Yadav S, Vyas B, Shah P. Eudragit S-100 surface engineered nanostructured lipid carriers for colon targeting of 5-fluorouracil: optimization and in vitro and in vivo characterization. AAPS PharmSciTech 2021; 22(6): 216.
[http://dx.doi.org/10.1208/s12249-021-02099-3] [PMID: 34386888]
[69]
Sharma T, Katare OP, Jain A, et al. QbD-steered development of biotin-conjugated nanostructured lipid carriers for oral delivery of chrysin: role of surface modification for improving biopharmaceutical performance. Colloids Surf B Biointerfaces 2021; 197: 111429.
[http://dx.doi.org/10.1016/j.colsurfb.2020.111429] [PMID: 33130524]
[70]
Xu C, Wang P, Zhang J, Tian H, Park K, Chen X. Pulmonary codelivery of doxorubicin and siRNA by pH-sensitive nanoparticles for therapy of metastatic lung cancer. Small 2015; 11(34): 4321-33.
[http://dx.doi.org/10.1002/smll.201501034] [PMID: 26136261]
[71]
Li N, Zhao L, Qi L, Li Z, Luan Y. Polymer assembly: Promising carriers as co-delivery systems for cancer therapy. Prog Polym Sci 2016; 58: 1-26.
[http://dx.doi.org/10.1016/j.progpolymsci.2015.10.009]
[72]
Li Y, Thambi T, Lee DS. Co-delivery of drugs and genes using polymeric nanoparticles for synergistic cancer therapeutic effects. Adv Healthc Mater 2018; 7(1): 1700886.
[http://dx.doi.org/10.1002/adhm.201700886] [PMID: 28941203]
[73]
Patel NR, Pattni BS, Abouzeid AH, Torchilin VP. Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev 2013; 65(13-14): 1748-62.
[http://dx.doi.org/10.1016/j.addr.2013.08.004] [PMID: 23973912]
[74]
Sun W, Chen X, Xie C, et al. Co-delivery of doxorubicin and Anti-BCL-2 siRNA by pH-responsive polymeric vector to overcome drug resistance in in vitro and in vivo hepg2 hepatoma model. Biomacromolecules 2018; 19(6): 2248-56.
[http://dx.doi.org/10.1021/acs.biomac.8b00272] [PMID: 29690766]
[75]
Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 2012; 33(2): 583-91.
[http://dx.doi.org/10.1016/j.biomaterials.2011.09.061 ] [PMID: 22014944]
[76]
Akhtar S. Oral delivery of siRNA and antisense oligonucleotides. J Drug Target 2009; 17(7): 491-5.
[http://dx.doi.org/10.1080/10611860903057674] [PMID: 19530907]
[77]
Majumder J, Minko T. Multifunctional lipid-based nanoparticles for codelivery of anticancer drugs and siRNA for treatment of non-small cell lung cancer with different level of resistance and EGFR mutations. Pharmaceutics 2021; 13(7): 1063.
[http://dx.doi.org/10.3390/pharmaceutics13071063 ] [PMID: 34371754]
[78]
Imam SS, Alshehri S, Ghoneim MM, et al. Recent advancement in chitosan-based nanoparticles for improved oral bioavailability and bioactivity of phytochemicals: Challenges and perspectives. Polymers (Basel) 2021; 13(22): 4036.
[http://dx.doi.org/10.3390/polym13224036] [PMID: 34833334]
[79]
Gao X, Zhang J, Xu Q, Huang Z, Wang Y, Shen Q. Hyaluronic acid-coated cationic nanostructured lipid carriers for oral vincristine sulfate delivery. Drug Dev Ind Pharm 2017; 43(4): 661-7.
[http://dx.doi.org/10.1080/03639045.2016.1275671] [PMID: 28043185]
[80]
Fang G, Tang B, Chao Y, et al. Cysteine-functionalized nanostructured lipid carriers for oral delivery of docetaxel: a permeability and pharmacokinetic study. Mol Pharm 2015; 12(7): 2384-95.
[http://dx.doi.org/10.1021/acs.molpharmaceut.5b00081] [PMID: 25974386]
[81]
Singh A, Neupane YR, Mangla B, Kohli K. Nanostructured lipid carriers for oral bioavailability enhancement of exemestane: formulation design, in vitro, ex vivo, and in vivo studies. J Pharm Sci 2019; 108(10): 3382-95.
[http://dx.doi.org/10.1016/j.xphs.2019.06.003] [PMID: 31201904]
[82]
Liu Q, Li J, Pu G, Zhang F, Liu H, Zhang Y. Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy. Drug Deliv 2016; 23(4): 1364-8.
[http://dx.doi.org/10.3109/10717544.2015.1031295 ] [PMID: 25874959]
[83]
Homayun B, Lin X, Choi HJ. Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics 2019; 11(3): 129.
[http://dx.doi.org/10.3390/pharmaceutics11030129 ] [PMID: 30893852]
[84]
Kumar MNVR, Sood AK. Editorial - Metronomic chemotherapy. Cancer Lett 2017; 400(400): 203.
[http://dx.doi.org/10.1016/j.canlet.2017.03.003] [PMID: 28315702]
[85]
Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng Transl Med 2019; 4(3): e10143.
[http://dx.doi.org/10.1002/btm2.10143] [PMID: 31572799]
[86]
Patel K, Foster NR, Farrell A, et al. Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature. J Cancer Educ 2013; 28(4): 770-6.
[http://dx.doi.org/10.1007/s13187-013-0511-z] [PMID: 23872949]
[87]
Salvioni L, Rizzuto MA, Bertolini JA, Pandolfi L, Colombo M, Prosperi D. Thirty years of cancer nanomedicine: Success, frustration, and hope. Cancers 2019; 11(12): 1855.
[http://dx.doi.org/10.3390/cancers11121855] [PMID: 31769416]
[88]
Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7(8): 455-65.
[http://dx.doi.org/10.1038/nrclinonc.2010.82] [PMID: 20531380]
[89]
Simsek C, Esin E, Yalcin S. Metronomic chemotherapy: a systematic review of the literature and clinical experience. J Oncol 2019; 2019: 1-31.
[http://dx.doi.org/10.1155/2019/5483791] [PMID: 31015835]
[90]
Rahman HS, Rasedee A, Othman HH, et al. Acute toxicity study of zerumbone-loaded nanostructured lipid carrier on BALB/c mice model. BioMed Res Int 2014; 2014: 1-15.
[http://dx.doi.org/10.1155/2014/563930] [PMID: 25276798]
[91]
Mendes LP, Delgado JMF, Costa ADA, et al. Biodegradable nanoparticles designed for drug delivery: The number of nanoparticles impacts on cytotoxicity. Toxicol In Vitro 2015; 29(6): 1268-74.
[http://dx.doi.org/10.1016/j.tiv.2014.12.021] [PMID: 25596133]
[92]
Elmowafy M, Shalaby K, Badran MM, Ali HM, Abdel-Bakky MS, Ibrahim HM. Multifunctional carbamazepine loaded nanostructured lipid carrier (NLC) formulation. Int J Pharm 2018; 550(1-2): 359-71.
[http://dx.doi.org/10.1016/j.ijpharm.2018.08.062] [PMID: 30179701]

Rights & Permissions Print Cite
Article Metrics
16
2
© 2024 Bentham Science Publishers | Privacy Policy